Anti-Human CD45/PTPRC Antibody (BC8), FITC

Introduction

The Anti-Human CD45/PTPRC Antibody (BC8), FITC is a type of monoclonal antibody that specifically targets the CD45/PTPRC protein found on the surface of human immune cells. This antibody is widely used in both research and therapeutic applications due to its high specificity and effectiveness in detecting and targeting CD45/PTPRC.

Structure of Anti-Human CD45/PTPRC Antibody (BC8), FITC

The Anti-Human CD45/PTPRC Antibody (BC8), FITC is a type of monoclonal antibody, meaning it is produced by a single clone of immune cells and is highly specific for its target antigen. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The variable regions of the antibody, responsible for binding to the CD45/PTPRC protein, are located at the tips of the heavy and light chains.
The FITC (fluorescein isothiocyanate) molecule is attached to the antibody through a chemical reaction, allowing for easy detection and visualization of the antibody when used in experiments.

Activity of Anti-Human CD45/PTPRC Antibody (BC8), FITC

The main activity of Anti-Human CD45/PTPRC Antibody (BC8), FITC is its ability to specifically bind to the CD45/PTPRC protein. CD45/PTPRC is a protein tyrosine phosphatase that is present on the surface of all human immune cells, including T cells, B cells, and natural killer cells. It plays a crucial role in regulating the activation and function of these immune cells.
By binding to CD45/PTPRC, the Anti-Human CD45/PTPRC Antibody (BC8), FITC can be used to detect and isolate specific immune cell populations, as well as to block the function of CD45/PTPRC in experiments. This allows for a better understanding of the role of CD45/PTPRC in immune responses and diseases.

Application of Anti-Human CD45/PTPRC Antibody (BC8), FITC

Therapeutic Target

CD45/PTPRC has been identified as a potential therapeutic target for various immune-related diseases, such as autoimmune disorders and cancer. The Anti-Human CD45/PTPRC Antibody (BC8), FITC can be used in the development of targeted therapies that specifically block the function of CD45/PTPRC on immune cells, potentially leading to more effective and less toxic treatments.

Research Use

The Anti-Human CD45/PTPRC Antibody (BC8), FITC is widely used in research studies to investigate the role of CD45/PTPRC in immune responses and diseases. It can be used in flow cytometry to identify and isolate specific immune cell populations, as well as in immunohistochemistry to visualize the distribution and expression of CD45/PTPRC in tissues.
Additionally, the Anti-Human CD45/PTPRC Antibody (BC8), FITC can be used in functional studies to block the function of CD45/PTPRC and assess its impact on immune cell activation and function. This antibody has been used in a variety of research areas, including immunology, cancer biology, and infectious diseases.

Conclusion

The Anti-Human CD45/PTPRC Antibody (BC8), FITC is a highly specific and effective antibody that targets the CD45/PTPRC protein on human immune cells. Its structure, activity, and application make it a valuable tool in both research and therapeutic settings.